HIV-1 integrase (IN) is a primary target for combination antiretroviral therapy. Only a limited
number of studies report on the emergence of resistance-associated mutations (RAMs) in …

Background Antiretroviral therapy (ART) regimens containing integrase strand transfer
inhibitors (INSTIs) have become the recommended treatment for human immunodeficiency …

The routine use of integrase inhibitors in sub-Saharan Africa where HIV-1 non-B viruses
predominate is limited, but evaluating their effectiveness on HIV-1 subtypes and CRFs that …

Abstract Introduction Sub-Saharan African countries are introducing integrase strand
transfer inhibitors (INSTIs) in their ART programmes as the preferred first-line regimen, and …

BACKGROUND: Antiretroviral therapy containing an integrase strand transfer inhibitor plus
two Nucleoside Reverse Transcriptase inhibitors has now been recommended for treatment …

Objectives The aim of the study was to analyse the prevalence of integrase resistance
mutations in integrase strand transfer inhibitor (INSTI)‐experienced HIV‐1‐infected patients …

Objectives: Integrase strand transfer inhibitor (INSTI) is a new class of antiretroviral (ARV)
drugs designed to block the action of the integrase viral enzyme, which is responsible for …

There has been no systematic review of the prevalence of transmitted integrase strand
transfer inhibitor (INSTI) resistance. We systematically searched the English-language …

Background Roll-out of Integrase Strand Transfer Inhibitors (INSTIs) such as dolutegravir for
HIV combination antiretroviral therapy (cART) in sub-Saharan Africa necessitates the …

Widespread introduction of HIV integrase inhibitors into clinical care may result in
appearance of drug resistance mutations affecting treatment outcome. The aim of our study …